 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 748 | 回復(fù): 5 | |||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | |||
seen163新蟲 (初入文壇)
|
[交流]
【求助】求3篇nature全文 已有4人參與
|
||
|
第一篇：Nature Reviews Drug Discovery 9, 431 (June 2010) 題目：Anticancer drugs: A Notch closer 作者：Sarah Crunkhorn 第2篇：Nature Reviews Drug Discovery 9, 432-433 (June 2010) 題目：Antiviral drugs: New oral HCV drug shows promise 作者：Man Tsuey Tse 第3篇：Nature Medicine 16, 614 (2010) doi:10.1038/nm0610-614b 題目：Diabetes drug woes spell trouble for the entire drug family 作者：Meredith Wadman |
回復(fù)此樓» 猜你喜歡
材料考研調(diào)劑
已經(jīng)有3人回復(fù)
-
材料調(diào)劑
已經(jīng)有12人回復(fù)
-
英一數(shù)一408，總分284，二戰(zhàn)真誠(chéng)求調(diào)劑
已經(jīng)有14人回復(fù)
-
085410 一志愿211 22408分?jǐn)?shù)359求調(diào)劑
已經(jīng)有4人回復(fù)
-
271求調(diào)劑
已經(jīng)有19人回復(fù)
-
385分 生物學(xué)（071000）求調(diào)劑
已經(jīng)有3人回復(fù)
-
一志愿安徽大學(xué)計(jì)算機(jī)科學(xué)與技術(shù)學(xué)碩，331分求調(diào)劑
已經(jīng)有3人回復(fù)
-
318求調(diào)劑，計(jì)算材料方向
已經(jīng)有8人回復(fù)
-
291求調(diào)劑
已經(jīng)有25人回復(fù)
-
一志愿北京科技大學(xué)085601材料工程英一數(shù)二初試總分335求調(diào)劑
已經(jīng)有6人回復(fù)
» 本主題相關(guān)價(jià)值貼推薦，對(duì)您同樣有幫助:
- 求2005年Nature Materials一篇
已經(jīng)有1人回復(fù)
hahaxuxingyu
木蟲 (小有名氣)
- 應(yīng)助: 4 (幼兒園)
- 金幣: 3266.7
- 散金: 2
- 帖子: 216
- 在線: 204小時(shí)
- 蟲號(hào): 1037143
- 注冊(cè): 2010-06-07
- 專業(yè): 藥物化學(xué)
3樓2010-06-12 17:29:17
xuxia778
金蟲 (正式寫手)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 1386.1
- 散金: 7
- 紅花: 1
- 帖子: 699
- 在線: 65.4小時(shí)
- 蟲號(hào): 504955
- 注冊(cè): 2008-02-16
- 性別: MM
- 專業(yè): 藥物分析
|
Aberrant signalling of the Notch pathway has been linked to numerous diseases, particularly many cancers. Although the potential of therapeutically targeting this pathway in cancer is being actively investigated, strategies used so far have been nonspecific or have been associated with significant side effects. Now, writing in Nature, Wu and colleagues characterize antibodies that selectively inhibit either NOTCH1 or NOTCH2 receptor signalling, exerting anticancer activity in mice without toxicity. The Notch family of transmembrane receptors comprises four members, with roles in the regulation of cell fate and growth. Following ligand binding, a conformational change in the receptor negative regulatory region (NRR) occurs, which ultimately facilitates initiation of the downstream Notch transcriptional programme. The authors therefore proposed that targeting this vital step in Notch pathway signalling may represent a new therapeutic approach. First, using phage display technology, the authors generated fully human immunoglobulin G1 NRR1-specific and NRR2-specific antibodies, which selectively inhibited NOTCH1 or NOTCH2 signalling. Receptor specificity was confirmed in vivo by the ability of the NRR1-specific and NRR2-specific antibodies to reduce the population of mouse T cells and splenic marginal zone B cells, respectively. Characterization of the crystal structure of the NRR1-specific antibody Fab fragment bound to human NRR1 suggested that the antibody mediates its inhibitory effects through interference with the conformational changes required for receptor activation. Next, the potential anticancer activity of the NRR1-specific antibody was investigated. Activating NOTCH1 mutations within the NRR are commonly observed in patients with T-cell acute lymphoblastic leukaemia (T-ALL) and allow ligand-independent signalling. In a NOTCH1 mutant T-ALL cell line, the NRR1-specific antibody significantly induced cell cycle arrest and reduced cell proliferation. Moreover, it also decreased cell size and increased apoptosis — effects that correlated with NOTCH1 inhibition. In addition, signalling activated by two of the most common T-ALL mutations (L1594P and L1575P), one of the strongest activating mutations (I1681N), as well as a PEST domain truncation (representative of another common cluster of T-ALL mutations), were inhibited in cell models. Screening a panel of 45 cancer cell lines for sensitivity to the NRR1-specific antibody also discovered activity in the MT-3 human colon cancer cell line, which was due to a single activating NOTCH1 mutation, A1702T. Moreover, in mouse xenograft T-ALL and colon cancer models, the antibody induced significant tumour regression and slowing of growth, respectively. Interestingly, it was shown to also act by an anti-angiogenic mechanism, in both in vitro and in vivo models. ADVERTISEMENT Finally, they assessed whether their antibodies induced intestinal toxicity, as this has been associated with pan-Notch inhibitors. Mice treated with both the NRR1-specific and NRR2-specific antibodies rapidly lost weight, whereas mice treated with either antibody alone maintained weight. Although the combination of both antibodies induced severe intestinal crypt goblet cell metaplasia, no such effect was detected with the NRR2-specific antibody alone, and only a mild effect was observed with the NRR1-specific antibody. It seems that Notch receptor-specific antibodies represent a significant advance over existing Notch pathway inhibitors, and may prove to be valuable in the future treatment of cancers, as well as other indications linked to dysregulated Notch signalling. |
4樓2010-06-13 06:27:18
seen163
新蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 30.8
- 帖子: 25
- 在線: 1.5小時(shí)
- 蟲號(hào): 512388
- 注冊(cè): 2008-02-26
- 專業(yè): 中藥生藥學(xué)/中藥材的儀器分
5樓2010-06-13 08:42:25
renxueqin
金蟲 (正式寫手)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 1436.3
- 散金: 55
- 紅花: 3
- 帖子: 485
- 在線: 65小時(shí)
- 蟲號(hào): 974253
- 注冊(cè): 2010-03-17
- 性別: MM
- 專業(yè): 中藥資源
6樓2010-06-13 10:45:03
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 一志愿北京科技，085601總分305求調(diào)劑 +9 | 半生瓜！ 2026-04-01 | 10/500 |
|
|---|---|---|---|---|
|
[考研] 289求調(diào)劑 +21 | 新時(shí)代材料 2026-03-27 | 23/1150 |
|
|
|
[考研] 279求調(diào)劑 +7 | 莫xiao 2026-04-01 | 7/350 |
|
|
|
[考研] 266分，一志愿電氣工程，本科材料，求材料專業(yè)調(diào)劑 +10 | 哇呼哼呼哼 2026-04-01 | 11/550 |
|
|
|
[考研] 材料調(diào)劑 +14 | 一樣YWY 2026-04-01 | 14/700 |
|
|
|
[考研] 349求調(diào)劑 +6 | 吃的不少 2026-04-01 | 6/300 |
|
|
|
[考研] 0856，材料與化工321分求調(diào)劑 +13 | 大饞小子 2026-03-27 | 14/700 |
|
|
|
[考研] 總分343，求生物學(xué)調(diào)劑 +6 | 深刻的凱撒 2026-03-26 | 6/300 |
|
|
|
[考研] 材料調(diào)劑 +11 | 一樣YWY 2026-03-31 | 11/550 |
|
|
|
[考研] 086000生物與醫(yī)藥298調(diào)劑求助 +4 | 元元青青 2026-03-31 | 6/300 |
|
|
|
[考研] 0855機(jī)械初試280求調(diào)劑 +3 | kazenotori 2026-03-31 | 3/150 |
|
|
|
[考研] 070300化學(xué)專業(yè)279調(diào)劑 +10 | 哈哈哈^_^ 2026-03-31 | 10/500 |
|
|
|
[考研] 求調(diào)劑 生物學(xué) 377分 +6 | zzll03 2026-03-31 | 6/300 |
|
|
|
[考研] 材料與化工272求調(diào)劑 +25 | 阿斯蒂芬2004 2026-03-28 | 25/1250 |
|
|
|
[考研] 調(diào)劑求院校招收 +7 | 鶴鯨鴿 2026-03-28 | 7/350 |
|
|
|
[考研] 291求調(diào)劑 +5 | Y-cap 2026-03-29 | 6/300 |
|
|
|
[考研] 298求調(diào)劑 +3 | 種圣賜 2026-03-29 | 3/150 |
|
|
|
[考研] 356求調(diào)劑 +3 | gysy?s?a 2026-03-28 | 3/150 |
|
|
|
[考研] 315分求調(diào)劑 +7 | 26考研上岸版26 2026-03-26 | 7/350 |
|
|
|
[考研] 272求調(diào)劑 +7 | 腳滑的守法公民 2026-03-27 | 7/350 |
|